Hepatitis C virus (HCV) infection is transmitted through blood or body fluids. There are six main types of HCV genotypes, and the HCV genotype in China is mainly type Ib. This type of infection is less responsive to interferon, more severe than other genotypes, and more likely to develop cirrhosis. The standard treatment recommended worldwide is pegylated interferon (PEG-IFN) combined with ribavirin, and the treatment course and response to PEG-IFN combined with ribavirin (RBV) is genotype specific. Genotypes II or III achieve 8o-9o% sustained viral response (svR), whereas genotype I achieves only 50-60% SVR. The current course of antiviral therapy for chronic hepatitis C is determined by genotype. PEG-IFN combined with RBV is used for 48 weeks in patients with genotype I and PEG-IFN combined with RBV for 24 weeks in genotype II or III. Patients with genotype I did not obtain complete early virological response (cEVR) or partial early virological response (pEVR, i.e., viral load decreased ≥2 log10 copies/ml at 12 weeks without achieving HCV RNA conversion) at 12 weeks of treatment, suggesting that the possibility of obtaining SVR is low and discontinuation of the drug is recommended. In recent years, it has been suggested that the duration of treatment below the detectable limit of virus is an important factor in determining the efficacy. By testing at 4 and 12 weeks, the response of patients can be judged, and thus different treatment regimens can be adopted. This has become a hot topic in clinical research, which emphasizes individualized treatment of chronic hepatitis C. Other anti-HCV drugs currently in clinical trials Albin interferon Albin interferon (Alb-IFN) is a new class of macromolecule-modified interferon with a longer half-life than PEG-IFN, and the results of a phase II clinical study showed that the SVR rate in the Alb-IFN treatment group was maintained at a higher rate and the relapse rate was reduced. However, there was an increase in the number of adverse events leading to discontinuation in the Alb-IFN-treated group compared to the PEG-IFN group. The RNA-dependent RNA polymerase (NS5B) inhibitor valopicitabine, which is a prodrug of the orally bioactive novel nucleoside analogue NM-107, directly inhibits HCV viral polymerase and binds to growing double-stranded viral RNA, thereby aborting RNA strand lengthening. At tolerable doses, it can reduce viral load to undetectable levels. In clinical trials, it has shown anti-HCV-1 infection activity alone or in combination with interferon, reducing the viral load of HCV RNA. And in vitro and in vivo trials have shown that. The combination of this product and interferon may produce synergistic antiviral effects. Ribavirin (RBV) precursor drug vimmidine is mainly metabolized in the liver. Phase II clinical trials are currently underway. The incidence of anemia is lower than ribavirin, but SVR is also lower than ribavirin rates. It is expected to be used in people who cannot tolerate ribavirin. levovirin is a 2nd generation RBV levo-enantiomer that retains immunomodulatory effects, enhances cytokine responses to Thl in vitro, stimulates a broad-spectrum antiviral state in vivo, and has a much lower adverse effect than RBV, with little accumulation in red blood cells. This may be because levovirin is not converted into mono-, di- or tri-phosphate intermediates in erythrocytes. It is now in phase I clinical trials.